Shots:
- The P-III ADVANCE and MOTIVATE studies involves assessing Risankizumab (600/ 1200mg) vs PBO in a mixed population of patients who had responded inadequately or are intolerant to conventional (non-bio-IR) or biologic (bio-IR) therapy and patients who had responded inadequately or were intolerant to biologic (bio-IR) therapy respectively
- Both the doses met its co-1EPs of clinical remission and endoscopic response @12wks. in both the studies. Detailed results were presented at DDW 2021
- Risankizumab is an IL-23 inhibitor, currently being evaluated as a treatment for adults with moderate to severe Crohn’s disease and other immune-mediated conditions
Click here to read full press release/ article | Ref: Abbvie | Image: Wall Street Journal
The post AbbVie Presents New Late-Breaking Data Analyses of Skyrizi (risankizumab) for Crohn’s Disease at DDW 2021 first appeared on PharmaShots.
